A real-world study of the efficacy and safety of DS-8201 in the treatment of advanced breast cancer and the exploration of biomarkers for predictive efficacy

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400093267

Enrollment

Unknown

Registered

2024-12-01

Start date

2023-11-03

Completion date

Unknown

Last updated

2024-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic advanced breast cancer

Interventions

Treatment group:DS8201

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. Metastatic breast cancer, which can be measured; 2. Have a traceable medical history record; 3. HER2 and ER/PR status information for immunohistochemistry detection; 4. Estimated survival time> 3 months; 5. HER2 low expression (1+/++) or overexpression;

Exclusion criteria

Exclusion criteria: 1. Incomplete medical history (please refer to the "Data Collection Form" for specific data requirements)

Design outcomes

Primary

Measure	Time frame
Primary lesion;	—

Secondary

Measure	Time frame
Adverse drug reactions;	—

Countries

China

Contacts

Public ContactSang Die,Yuan Peng

Sanhuan Cancer Hospital of beijing Chaoyang District

sangdie0123@126.com+86 13552234679

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026